Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. Show More...
-
Website https://www.xenon-pharma.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 28.85 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -1.32 -0.47 0.39 3.28 -1.1 -1.48 -1.72 -1.63 -1.54 -1.34 Dividends USD Payout Ratio % * Shares Mil 10.0 10.0 10.0 4.0 14.0 15.0 18.0 19.0 26.0 28.0 Book Value Per Share * USD -4.76 -5.83 -5.78 -7.25 3.85 2.38 5.15 Free Cash Flow Per Share * USD -0.02 -1.18 -1.41 -1.49 -1.97 -1.26 Return on Assets % -6.79 20.43 18.35 -20.81 -34.99 -54.05 -37.52 -29.64 -20.69 Financial Leverage (Average) 1.2 1.05 1.06 1.28 1.28 1.75 1.32 Return on Equity % -23.54 -36.81 -61.51 -48.09 -44.52 -27.47 Return on Invested Capital % -24.35 -37.62 -54.97 -41.2 -37.9 -25.37 Interest Coverage -130.78 -45.25 189.0 -23.75 -28.02 -25.88 Current Ratio 3.16 2.74 5.95 21.88 18.68 10.98 29.48 3.34 4.82 Quick Ratio 3.15 2.73 5.9 21.2 18.3 10.8 29.03 3.28 4.77 Debt/Equity 0.17 0.16 0.14